$MD
Pediatrix Medical Group, Inc.

2015 Q4 Form 10-K Financial Statement

#000119312517038250 Filed on February 10, 2017

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2015 Q2
Revenue $741.7M $722.3M $676.6M
YoY Change 14.02% 15.29% 13.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $546.5M $530.2M $495.2M
YoY Change 15.78% 16.43% 14.36%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $18.15M $16.92M $15.55M
YoY Change 30.54% 48.98% 50.07%
% of Gross Profit
Operating Expenses $590.8M $571.1M $535.6M
YoY Change 15.97% 16.95% 14.97%
Operating Profit $151.0M $151.1M $141.0M
YoY Change 7.0% 9.4% 8.7%
Interest Expense $8.493M $6.201M $5.149M
YoY Change 156.35% 207.13% 135.33%
% of Operating Profit 5.63% 4.1% 3.65%
Other Income/Expense, Net -$6.965M -$4.850M -$4.020M
YoY Change 214.73% 563.47% 136.05%
Pretax Income $144.0M $146.3M $136.9M
YoY Change 3.69% 6.45% 7.01%
Income Tax $51.58M $55.64M $52.89M
% Of Pretax Income 35.82% 38.04% 38.62%
Net Earnings $92.70M $90.78M $84.13M
YoY Change 4.87% 5.31% 6.47%
Net Earnings / Revenue 12.5% 12.57% 12.43%
Basic Earnings Per Share $1.00 $0.98 $0.91
Diluted Earnings Per Share $0.99 $0.97 $0.90
COMMON SHARES
Basic Shares Outstanding 92.79M shares 92.95M shares 92.50M shares
Diluted Shares Outstanding 93.54M shares 93.65M shares 93.50M shares

Balance Sheet

Concept 2015 Q4 2015 Q3 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.40M $68.90M $70.40M
YoY Change 11.85% -12.9% 178.26%
Cash & Equivalents $51.57M $60.92M $65.32M
Short-Term Investments $8.900M $8.000M $5.100M
Other Short-Term Assets $12.97M $11.98M $10.72M
YoY Change 64.13% 10.76% -1.48%
Inventory
Prepaid Expenses $9.639M $10.04M $9.256M
Receivables $444.7M $406.8M $380.5M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $527.8M $573.2M $525.5M
YoY Change 13.0% 19.15% 28.9%
LONG-TERM ASSETS
Property, Plant & Equipment $83.63M $82.87M $81.36M
YoY Change 26.63% 30.31% 35.2%
Goodwill $3.366B $3.348B $3.164B
YoY Change 21.25% 25.89% 25.74%
Intangibles $424.2M
YoY Change 114.1%
Long-Term Investments $63.30M $59.30M $61.90M
YoY Change -1.25% -4.05% 6.54%
Other Assets $82.15M $483.4M $442.5M
YoY Change 123.6% 127.53% 234.46%
Total Long-Term Assets $4.019B $3.973B $3.750B
YoY Change 27.96% 32.57% 35.52%
TOTAL ASSETS
Total Short-Term Assets $527.8M $573.2M $525.5M
Total Long-Term Assets $4.019B $3.973B $3.750B
Total Assets $4.547B $4.546B $4.275B
YoY Change 26.02% 30.71% 34.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.97M $22.34M $25.19M
YoY Change -32.99% 0.75% -0.77%
Accrued Expenses $373.8M $329.3M $261.5M
YoY Change 7.44% 18.41% 20.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00M $11.80M $12.00M
YoY Change 0.0% 3833.33% 11900.0%
Total Short-Term Liabilities $428.8M $404.6M $311.8M
YoY Change 3.0% 22.87% 18.65%
LONG-TERM LIABILITIES
Long-Term Debt $1.260B $1.351B $1.285B
YoY Change 126.1% 368.6% 619.43%
Other Long-Term Liabilities $52.29M $57.22M $64.42M
YoY Change -11.32% 4.98% 8.94%
Total Long-Term Liabilities $1.313B $57.22M $64.42M
YoY Change 112.96% 4.98% 8.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $428.8M $404.6M $311.8M
Total Long-Term Liabilities $1.313B $57.22M $64.42M
Total Liabilities $2.109B $2.213B $2.055B
YoY Change 57.1% 127.39% 166.96%
SHAREHOLDERS EQUITY
Retained Earnings $1.510B $1.415B $1.321B
YoY Change 9.7% -11.83% -12.99%
Common Stock $927.2M $918.5M $898.5M
YoY Change 4.43% 91473.38% 89573.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.438B $2.333B $2.220B
YoY Change
Total Liabilities & Shareholders Equity $4.547B $4.546B $4.275B
YoY Change 26.02% 30.71% 34.67%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2015 Q2
OPERATING ACTIVITIES
Net Income $92.70M $90.78M $84.13M
YoY Change 4.87% 5.31% 6.47%
Depreciation, Depletion And Amortization $18.15M $16.92M $15.55M
YoY Change 30.54% 48.98% 50.07%
Cash From Operating Activities $104.1M $172.2M $146.1M
YoY Change -41.78% 8.03% 8.87%
INVESTING ACTIVITIES
Capital Expenditures -$7.200M -$7.200M -$7.300M
YoY Change 7.46% 100.0% 128.12%
Acquisitions
YoY Change
Other Investing Activities -$17.40M -$237.1M -$528.2M
YoY Change -87.04% 10.79% 681.36%
Cash From Investing Activities -$24.60M -$244.3M -$535.5M
YoY Change -82.55% 12.22% 657.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -88.90M 67.80M 404.5M
YoY Change 44.32% -39.63% -716.62%
NET CHANGE
Cash From Operating Activities 104.1M 172.2M 146.1M
Cash From Investing Activities -24.60M -244.3M -535.5M
Cash From Financing Activities -88.90M 67.80M 404.5M
Net Change In Cash -9.400M -4.300M 15.10M
YoY Change -60.5% -107.96% -819.05%
FREE CASH FLOW
Cash From Operating Activities $104.1M $172.2M $146.1M
Capital Expenditures -$7.200M -$7.200M -$7.300M
Free Cash Flow $111.3M $179.4M $153.4M
YoY Change -40.0% 10.06% 11.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
600000000
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
93793665 shares
CY2016Q2 dei Entity Public Float
EntityPublicFloat
6630916089
CY2016Q3 md Unrecognized Tax Benefits Impact Effective Tax Rate
UnrecognizedTaxBenefitsImpactEffectiveTaxRate
10600000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31137000
CY2013Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
158691000
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2342988000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
14902000
CY2013Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
712285
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47928000
CY2014Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
29000000
CY2014Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
168369000
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2265566000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17165000
CY2014Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
848767
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
395807000
CY2015Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
567195000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Deferred Tax Liabilities Deferred Expense Reserves And Accruals
DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
55046000
CY2015Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
21081000
CY2015Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
26382000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
119334000
CY2015Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1283500000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13662000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
93739000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93739000 shares
CY2015Q4 us-gaap Assets
Assets
4547214000
CY2015Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
400000
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
373042000
CY2015Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
6693000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2723000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
66655000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
527769000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1552000
CY2015Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
311303000
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3800000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
82928000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
926235000
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
154005000
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1129301000
CY2015Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
4299000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51572000
CY2015Q4 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
14500000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
444737000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
937000
CY2015Q4 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
24900000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
21969000
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
233499000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
219037000
CY2015Q4 us-gaap Business Acquisition Equity Interest Issued Or Issuable Value Assigned
BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
7800000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
220589000
CY2015Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
1883000
CY2015Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
2416000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
51505000
CY2015Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
188956000
CY2015Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1574038000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
136600000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2015Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
63288000
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1260404000
CY2015Q4 us-gaap Long Term Debt
LongTermDebt
1270404000
CY2015Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
176532000
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
142976000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
10000000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
12968000
CY2015Q4 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
60383000
CY2015Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
343500000
CY2015Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
7000000
CY2015Q4 us-gaap Land
Land
6683000
CY2015Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
9300000
CY2015Q4 us-gaap Liabilities
Liabilities
2109368000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4547214000
CY2015Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
25995000
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
424219000
CY2015Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
169903000
CY2015Q4 us-gaap Goodwill
Goodwill
3366150000
CY2015Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8853000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
52289000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
428771000
CY2015Q4 us-gaap Minority Interest
MinorityInterest
318000
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9639000
CY2015Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
916100000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32145000
CY2015Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
11883000
CY2015Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
400000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82154000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
202527000
CY2015Q4 us-gaap Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
2905000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
83634000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
202968000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
2437528000
CY2015Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
3116000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.96
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1013791 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
61.50
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2437846000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
18447000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1510356000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
13096000
CY2015Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1129301
CY2015Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
135100000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2655000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
585387 shares
CY2015Q4 md Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
0
CY2015Q4 md Debt Instrument Carrying Amount Non Current
DebtInstrumentCarryingAmountNonCurrent
1273500000
CY2015Q4 md Money Market Funds At Fair Value
MoneyMarketFundsAtFairValue
13900000
CY2015Q4 md Accrued Professional Liability
AccruedProfessionalLiability
67400000
CY2015Q4 md Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
13096000
CY2015Q4 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
395807000
CY2015Q4 md Debt Instrument Carrying Amount Current
DebtInstrumentCarryingAmountCurrent
10000000
CY2015Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
58979000
CY2015Q4 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
919320000
CY2015Q4 md Accrued Contingent Consideration Liability Current
AccruedContingentConsiderationLiabilityCurrent
13565000
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
407938000
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
871821000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
1193000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Deferred Tax Liabilities Deferred Expense Reserves And Accruals
DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals
53771000
CY2016Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
18957000
CY2016Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
26572000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
2054000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
143708000
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1713500000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13726000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
93718000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93718000 shares
CY2016Q4 us-gaap Assets
Assets
5339400000
CY2016Q4 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
179800000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
84000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
435388000
CY2016Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1023000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
57060000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
61374000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1610000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
62212000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
587128000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4014000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
380594000
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3500000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
103525000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
974304000
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
207552000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1224366000
CY2016Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
3550000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55698000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
51298000
CY2016Q4 us-gaap Cash Surrender Value Fair Value Disclosure
CashSurrenderValueFairValueDisclosure
15800000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
495276000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
63000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
937000
CY2016Q4 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
17300000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
28474000
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
220635000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
227836000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
44896000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
231850000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2054000
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
1496000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
156000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
49156000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
227802000
CY2016Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1719642000
CY2016Q4 us-gaap Decrease In Unrecognized Tax Benefits Is Reasonably Possible
DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
2100000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
122371000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
750000000
CY2016Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
130000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2016Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
78975000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1682132000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
8960000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
13132000
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
1702132000
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0
CY2016Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
173080000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
203292000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
20000000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13817000
CY2016Q4 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
70005000
CY2016Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
783500000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
35465000
CY2016Q4 us-gaap Land
Land
6683000
CY2016Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
1400000
CY2016Q4 us-gaap Liabilities
Liabilities
2578633000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5339400000
CY2016Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
28972000
CY2016Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
11286000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
45174000
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
668529000
CY2016Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
213521000
CY2016Q4 us-gaap Goodwill
Goodwill
3845157000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
448949000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
17602000
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
130000000
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11051000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50950000
CY2016Q4 us-gaap Increase In Unrecognized Tax Benefits Is Reasonably Possible
IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
2200000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
19791000
CY2016Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
22054000
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
30000000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56543000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
65560000
CY2016Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
202052000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15700000
CY2016Q4 us-gaap Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
8970000
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
20000000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
27421000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
103068000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
246776000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
28.33
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
2760767000
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1621000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.33
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
410286 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
946329 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
66.98
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2760767000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9469000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1785526000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4500000 shares
CY2016Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
9500000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15700000
CY2016Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
11368000
CY2016Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1224366
CY2016Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
128100000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4511000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
410286 shares
CY2016Q4 md Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
0
CY2016Q4 md Debt Instrument Carrying Amount Non Current
DebtInstrumentCarryingAmountNonCurrent
1693500000
CY2016Q4 md Money Market Funds At Fair Value
MoneyMarketFundsAtFairValue
12400000
CY2016Q4 md Line Of Credit Facility Potential Increase In Borrowing Capacity
LineOfCreditFacilityPotentialIncreaseInBorrowingCapacity
2200000000
CY2016Q4 md Accrued Professional Liability
AccruedProfessionalLiability
74000000
CY2016Q4 md Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
11368000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45990000
CY2014 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
170007000
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.18
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0015 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0059 pure
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
30100000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
21109000
CY2014 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
17500000
CY2016Q4 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
407938000
CY2016Q4 md Debt Instrument Carrying Amount Current
DebtInstrumentCarryingAmountCurrent
20000000
CY2016Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
67830000
CY2016Q4 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
900128000
CY2016Q4 md Accrued Contingent Consideration Liability Current
AccruedContingentConsiderationLiabilityCurrent
6566000
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
167745000
CY2014 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
17462000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000 shares
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1230000
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0033 pure
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31719000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
16791000
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0274 pure
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31700000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2262000
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
297000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
247527000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.22
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
34300000
CY2014 us-gaap Depreciation
Depreciation
15900000
CY2014 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
1244000
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3763 pure
CY2014 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
17479000
CY2014 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-417000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2559000
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3500 pure
CY2014 us-gaap Proceeds And Excess Tax Benefit From Sharebased Compensation
ProceedsAndExcessTaxBenefitFromSharebasedCompensation
30100000
CY2014 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
6998000
CY2014 us-gaap Malpractice Loss Contingency Claims Incurred Net
MalpracticeLossContingencyClaimsIncurredNet
13583000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
27800000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4383000
CY2014 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
26884000
CY2014 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
1025000
CY2014 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2492000
CY2014 us-gaap Operating Expenses
OperatingExpenses
1925914000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
317281000
CY2014 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-78000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-503604000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
508616000
CY2014 us-gaap Interest Expense
InterestExpense
8891000
CY2014 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
4281000
CY2014 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
20735000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
57018000
CY2014 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1754500000
CY2014 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
488429000
CY2014 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
479394000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1506000
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1299000 shares
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
512999000
CY2014 us-gaap Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
13290000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
97754000
CY2014 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
2438913000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
66039000
CY2014 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-907000
CY2014 us-gaap Investment Income Net
InvestmentIncomeNet
2728000
CY2014 us-gaap Malpractice Loss Contingency Period Increase Decrease
MalpracticeLossContingencyPeriodIncreaseDecrease
9284000
CY2014 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
161841000
CY2014 us-gaap Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
293000
CY2014 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1780000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
191413000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
422641000
CY2014 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
18061000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42876000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
57.73
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
42876000
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99887000 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
28200000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
40000
CY2014 us-gaap Valuation Allowances And Reserves Adjustments
ValuationAllowancesAndReservesAdjustments
-5266955
CY2014 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
488429000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3750000
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98588000 shares
CY2014 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1527000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
38800000
CY2014 us-gaap Profit Loss
ProfitLoss
317203000
CY2014 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
21406000
CY2014 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1213500000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
31719000
CY2014 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
159000
CY2014 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
5403437
CY2014 us-gaap Interest Paid Net
InterestPaidNet
7323000
CY2014 md Payment Of Contingent Consideration Liability Financing
PaymentOfContingentConsiderationLiabilityFinancing
11740000
CY2014 md Health Organization Revenue Gross
HealthOrganizationRevenueGross
7662556000
CY2014 md Contributions From Noncontrolling Interest
ContributionsFromNoncontrollingInterest
1025000
CY2014 md Stock Issued During Period Value Restricted Stock Contingent Consideration
StockIssuedDuringPeriodValueRestrictedStockContingentConsideration
705000
CY2014 md Payment Of Contingent Consideration Liability Operating
PaymentOfContingentConsiderationLiabilityOperating
4071000
CY2014 md Provision Adjustment For Losses Related To Current Year
ProvisionAdjustmentForLossesRelatedToCurrentYear
39386000
CY2014 md Malpractice Loss Contingency Provision For Losses
MalpracticeLossContingencyProvisionForLosses
23261000
CY2014 md Provision Adjustment For Losses Related To Prior Year
ProvisionAdjustmentForLossesRelatedToPriorYear
-16125000
CY2014 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1543395000
CY2014 md Contractual Adjustments And Uncollectibles
ContractualAdjustmentsAndUncollectibles
5403437000
CY2014 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
89002000
CY2014 md Hospital Contract Administrative Fees
HospitalContractAdministrativeFees
179794000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
168596000
CY2015 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
11583000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1541000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0034 pure
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32129000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3644000
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0297 pure
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32100000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0029 pure
CY2015 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
3.75
CY2015 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
3276266000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1800000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
12866000
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
1628000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
305915000
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.61
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
39700000
CY2015 us-gaap Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
114306 shares
CY2015 us-gaap Depreciation
Depreciation
22200000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64228000
CY2015 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
181462000
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.58
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.0041 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0043 pure
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
42000000
CY2015 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
23000000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
20948000
CY2015 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
853300000
CY2015 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
348788000
CY2015 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
11600000
CY2015 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
3135000
CY2015 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
2062000
CY2015 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
590000000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3776 pure
CY2015 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
11583000
CY2015 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
13000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
14494000
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3500 pure
CY2015 us-gaap Proceeds And Excess Tax Benefit From Sharebased Compensation
ProceedsAndExcessTaxBenefitFromSharebasedCompensation
6100000
CY2015 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-4101000
CY2015 us-gaap Malpractice Loss Contingency Claims Incurred Net
MalpracticeLossContingencyClaimsIncurredNet
15217000
CY2015 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
750000000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
31600000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18139000
CY2015 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
33980000
CY2015 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2654000
CY2015 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
93960000 shares
CY2015 us-gaap Operating Expenses
OperatingExpenses
2222128000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
336320000
CY2015 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-629000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
539729000
CY2015 us-gaap Interest Expense
InterestExpense
23110000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-848000000
CY2015 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
14190000
CY2015 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
31956000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
55391000
CY2015 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
818300000
CY2015 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2121500000
CY2015 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
235051000
CY2015 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
818903000
CY2015 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
12 Acquisition
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4905000
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
883000 shares
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
557868000
CY2015 us-gaap Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
13835000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
482943000
CY2015 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
2779996000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7874000
CY2015 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-98000
CY2015 us-gaap Investment Income Net
InvestmentIncomeNet
1844000
CY2015 us-gaap Malpractice Loss Contingency Period Increase Decrease
MalpracticeLossContingencyPeriodIncreaseDecrease
-2064000
CY2015 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
181005000
CY2015 us-gaap Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
1382000
CY2015 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3127000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
204038000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
368701000
CY2015 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
27073000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20128000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
70.44
CY2015 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
3.71
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20128000
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93960000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
31600000
CY2015 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
3400000 shares
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
467000
CY2015 us-gaap Valuation Allowances And Reserves Adjustments
ValuationAllowancesAndReservesAdjustments
-6108661
CY2015 us-gaap Stock Issued1
StockIssued1
7800000
CY2015 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
235051000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3675000
CY2015 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1200000
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93077000 shares
CY2015 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1692000
CY2015 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
93077000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11300000
CY2015 us-gaap Profit Loss
ProfitLoss
335691000
CY2015 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
22576000
CY2015 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2156000000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
32129000
CY2015 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2171000
CY2015 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
6389195
CY2015 us-gaap Interest Paid Net
InterestPaidNet
20367000
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
1168000
CY2015 md Payment Of Contingent Consideration Liability Financing
PaymentOfContingentConsiderationLiabilityFinancing
12856000
CY2015 md Health Organization Revenue Gross
HealthOrganizationRevenueGross
8942957000
CY2015 md Effective Income Tax Rate Continuing Operations Excluding Impact Of Tax Settlement
EffectiveIncomeTaxRateContinuingOperationsExcludingImpactOfTaxSettlement
0.3776 pure
CY2015 md Payment Of Contingent Consideration Liability Operating
PaymentOfContingentConsiderationLiabilityOperating
1439000
CY2015 md Provision Adjustment For Losses Related To Current Year
ProvisionAdjustmentForLossesRelatedToCurrentYear
39204000
CY2015 md Malpractice Loss Contingency Provision For Losses
MalpracticeLossContingencyProvisionForLosses
13407000
CY2015 md Number Of Physician Group Practices Acquired
NumberOfPhysicianGroupPracticesAcquired
10 Company
CY2015 md Provision Adjustment For Losses Related To Prior Year
ProvisionAdjustmentForLossesRelatedToPriorYear
-25797000
CY2015 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1753505000
CY2015 md Contractual Adjustments And Uncollectibles
ContractualAdjustmentsAndUncollectibles
6389195000
CY2015 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
98480000
CY2015 md Stock Issued During Period Value Restricted Stock Acquisition Consideration
StockIssuedDuringPeriodValueRestrictedStockAcquisitionConsideration
7800000
CY2015 md Hospital Contract Administrative Fees
HospitalContractAdministrativeFees
226234000
CY2015 md Accrued Professional Liabilities Assumed Through Acquisition
AccruedProfessionalLiabilitiesAssumedThroughAcquisition
35968000
CY2015 md Number Of Thirdparty Receivables Companies Acquired
NumberOfThirdpartyReceivablesCompaniesAcquired
1 Company
CY2015 md Number Of Teleradiology Physician Services Acquired
NumberOfTeleradiologyPhysicianServicesAcquired
1 Company
CY2016 dei Entity Registrant Name
EntityRegistrantName
MEDNAX, INC.
CY2016 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
4241000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2000 shares
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
166758000
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0000893949
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4816000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0043 pure
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34000000
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4126000
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0294 pure
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34000000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0048 pure
CY2016 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
3.57
CY2016 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
3336120000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2673000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
15596000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
2553000
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
304600000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
372572000
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.52
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
45200000
CY2016 us-gaap Depreciation
Depreciation
29000000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
89264000
CY2016 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
182354000
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.49
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0006 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0211 pure
CY2016 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
60300000
CY2016 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
15000000
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
4296000
CY2016 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
759600000
CY2016 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
329720000
CY2016 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
4200000
CY2016 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
1619000
CY2016 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
2625000
CY2016 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
479000000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3680 pure
CY2016 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
4131000
CY2016 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
772000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
18149000
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3500 pure
CY2016 us-gaap Proceeds And Excess Tax Benefit From Sharebased Compensation
ProceedsAndExcessTaxBenefitFromSharebasedCompensation
4700000
CY2016 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-2234000
CY2016 us-gaap Malpractice Loss Contingency Claims Incurred Net
MalpracticeLossContingencyClaimsIncurredNet
13176000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
38000000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-57888000
CY2016 us-gaap Payments For Previous Acquisition
PaymentsForPreviousAcquisition
11800000
CY2016 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
60976000
CY2016 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-7405000
CY2016 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
93109000 shares
CY2016 us-gaap Operating Expenses
OperatingExpenses
2611472000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
324914000
CY2016 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-318000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
513799000
CY2016 us-gaap Interest Expense
InterestExpense
63092000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-821217000
CY2016 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
41325000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
34000000
CY2016 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2019-10-29
CY2016 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
756100000
CY2016 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1940000000
CY2016 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
61828000
CY2016 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
762302000
CY2016 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
15 Acquisition
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
783000
CY2016 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
687000 shares
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
571687000
CY2016 us-gaap Malpractice Loss Contingency Claims Incurred In Prior Periods
MalpracticeLossContingencyClaimsIncurredInPriorPeriods
12410000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
381565000
CY2016 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
3183159000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11617000
CY2016 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-10035000
CY2016 us-gaap Investment Income Net
InvestmentIncomeNet
2019000
CY2016 us-gaap Malpractice Loss Contingency Period Increase Decrease
MalpracticeLossContingencyPeriodIncreaseDecrease
-3452000
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
175962000
CY2016 us-gaap Malpractice Loss Contingency Claims Incurred In Period
MalpracticeLossContingencyClaimsIncurredInPeriod
766000
CY2016 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3185000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
189203000
CY2016 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: &quot;Times New Roman&quot;" size="2"><b>1.&#xA0;&#xA0;&#xA0;&#xA0;General:</b></font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: &quot;Times New Roman&quot;" size="2">The principal business activity of MEDNAX, Inc. (&#x201C;MEDNAX&#x201D; or the &#x201C;Company&#x201D;) and its subsidiaries is to provide neonatal, anesthesia, maternal-fetal and other pediatric subspecialties physician services. The Company has contracts with affiliated business corporations or professional associations, limited liability companies and partnerships (&#x201C;affiliated professional contractors&#x201D;), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">(i)&#xA0;fee-for-service</font></font>&#xA0;contracts, whereby hospitals agree, in exchange for the Company&#x2019;s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company&#x2019;s affiliated healthcare professionals, and (ii)&#xA0;administrative fee contracts, whereby the Company is assured a minimum revenue level.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: &quot;Times New Roman&quot;" size="2">MEDNAX also provides teleradiology services to hospital, health system and radiology group facilities in all 50 states, the District of Columbia and Puerto Rico through a network of affiliated radiologists. In addition to its national physician network, the Company also provides services nationwide to healthcare providers, including its own, through complementary businesses including a management services organization specializing in full-service revenue cycle management and a consulting services company.</font></p> </div>
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
443778000
CY2016 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
39264000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22022000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
66.18
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
67.90
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
175101 shares
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: &quot;Times New Roman&quot;" size="2"><b>Accounting Estimates and Assumptions</b></font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: medium; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: &quot;Times New Roman&quot;" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company&#x2019;s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company&#x2019;s professional liability risks, the fair value of goodwill, and liabilities for uncertain tax positions. Actual results could differ from those estimates.</font></p> </div>
CY2016 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
3.54
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
22022000
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93109000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
29800000
CY2016 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
900000 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
301000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
519448 shares
CY2016 us-gaap Valuation Allowances And Reserves Adjustments
ValuationAllowancesAndReservesAdjustments
-7368965
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
52957 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
5644000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
57.31
CY2016 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
61828000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2258000
CY2016 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
-9000000
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
27.08
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92422000 shares
CY2016 dei Trading Symbol
TradingSymbol
MD
CY2016 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
1966000
CY2016 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
92422000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
504943 shares
CY2016 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
6849000
CY2016 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1510000000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
34000000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6800000
CY2016 us-gaap Profit Loss
ProfitLoss
324596000
CY2016 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2130000
CY2016 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
7464030
CY2016 us-gaap Interest Paid Net
InterestPaidNet
60453000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
3927000
CY2016 md Payment Of Contingent Consideration Liability Financing
PaymentOfContingentConsiderationLiabilityFinancing
10740000
CY2016 md Health Organization Revenue Gross
HealthOrganizationRevenueGross
10374813000
CY2016 md Effective Income Tax Rate Continuing Operations Excluding Impact Of Tax Settlement
EffectiveIncomeTaxRateContinuingOperationsExcludingImpactOfTaxSettlement
0.3887 pure
CY2016 md Payment Of Contingent Consideration Liability Operating
PaymentOfContingentConsiderationLiabilityOperating
1037000
CY2016 md Business Combination Contingent Consideration Arrangements Time Period
BusinessCombinationContingentConsiderationArrangementsTimePeriod
P5Y
CY2016 md Provision Adjustment For Losses Related To Current Year
ProvisionAdjustmentForLossesRelatedToCurrentYear
38129000
CY2016 md Malpractice Loss Contingency Provision For Losses
MalpracticeLossContingencyProvisionForLosses
12701000
CY2016 md Number Of Anesthesiology Practices Acquired
NumberOfAnesthesiologyPracticesAcquired
8 Company
CY2016 md Number Of Physician Group Practices Acquired
NumberOfPhysicianGroupPracticesAcquired
13 Company
CY2016 md Provision Adjustment For Losses Related To Prior Year
ProvisionAdjustmentForLossesRelatedToPriorYear
-25428000
CY2016 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
2031220000
CY2016 md Cash And Cash Equivalents Maturity Description
CashAndCashEquivalentsMaturityDescription
90 days or less
CY2016 md Number Of Neonatology Practices Acquired
NumberOfNeonatologyPracticesAcquired
1 Company
CY2016 md Contractual Adjustments And Uncollectibles
ContractualAdjustmentsAndUncollectibles
7464030000
CY2016 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
118416000
CY2016 md Hospital Contract Administrative Fees
HospitalContractAdministrativeFees
272376000
CY2016 md Number Of Patient Engagement Software Company Acquired
NumberOfPatientEngagementSoftwareCompanyAcquired
1 Company
CY2016 md Number Of Pediatric Subspecialty Practices Acquired
NumberOfPediatricSubspecialtyPracticesAcquired
2 Company
CY2016 md Number Of Maternalfetal Medicine Practices Acquired
NumberOfMaternalfetalMedicinePracticesAcquired
1 Company
CY2016 md Number Of Pediatric Cardiology Practices Acquired
NumberOfPediatricCardiologyPracticesAcquired
1 Company
CY2016 md Number Of Thirdparty Receivables Companies Acquired
NumberOfThirdpartyReceivablesCompaniesAcquired
1 Company
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
67936000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.73
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13612000
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.72
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2304000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
524574000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
68707000
CY2015Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-118000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
112517000
CY2015Q1 us-gaap Interest Expense
InterestExpense
3267000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
114821000
CY2015Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
639395000
CY2015Q1 us-gaap Investment Income Net
InvestmentIncomeNet
142000
CY2015Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
821000
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43928000
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95325000 shares
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94231000 shares
CY2015Q1 us-gaap Profit Loss
ProfitLoss
68589000
CY2015Q1 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
419595000
CY2015Q1 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
23431000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
72401000
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.91
CY2015Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15549000
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.90
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4020000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
535631000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
84130000
CY2015Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-82000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
136937000
CY2015Q2 us-gaap Interest Expense
InterestExpense
5149000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
140957000
CY2015Q2 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
676588000
CY2015Q2 us-gaap Investment Income Net
InvestmentIncomeNet
384000
CY2015Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
745000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
52889000
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93495000 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92500000 shares
CY2015Q2 us-gaap Profit Loss
ProfitLoss
84048000
CY2015Q2 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
422803000
CY2015Q2 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
24878000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
89950000
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92182000 shares
CY2016Q2 us-gaap Profit Loss
ProfitLoss
82325000
CY2016Q2 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
484625000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19584000
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13051000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
628391000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
67899000
CY2016Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-128000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
111182000
CY2016Q1 us-gaap Interest Expense
InterestExpense
14463000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
124233000
CY2016Q1 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
752624000
CY2016Q1 us-gaap Investment Income Net
InvestmentIncomeNet
618000
CY2016Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
794000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43411000
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93091000 shares
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92269000 shares
CY2016Q1 us-gaap Profit Loss
ProfitLoss
67771000
CY2016Q1 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
491811000
CY2016Q1 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
27046000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
92116000
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.89
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20241000
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.89
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13859000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
623974000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
82427000
CY2016Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-102000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
133926000
CY2016Q2 us-gaap Interest Expense
InterestExpense
15058000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
147785000
CY2016Q2 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
771759000
CY2016Q2 us-gaap Investment Income Net
InvestmentIncomeNet
410000
CY2016Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
789000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51601000
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92945000 shares
CY2016Q2 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
26992000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
80185000
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.98
CY2015Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16918000
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.97
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4850000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
571143000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
90781000
CY2015Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-141000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
146280000
CY2015Q3 us-gaap Interest Expense
InterestExpense
6201000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
151130000
CY2015Q3 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
722273000
CY2015Q3 us-gaap Investment Income Net
InvestmentIncomeNet
567000
CY2015Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
784000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
55640000
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93646000 shares
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92949000 shares
CY2015Q3 us-gaap Profit Loss
ProfitLoss
90640000
CY2015Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
450033000
CY2015Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
24007000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
93457000
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.04
CY2016Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24185000
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.04
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16198000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
671115000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
96509000
CY2016Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-88000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
140693000
CY2016Q3 us-gaap Interest Expense
InterestExpense
17215000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
156891000
CY2016Q3 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
828006000
CY2016Q3 us-gaap Investment Income Net
InvestmentIncomeNet
221000
CY2016Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
796000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
44272000
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93146000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92604000 shares
CY2016Q3 us-gaap Profit Loss
ProfitLoss
96421000
CY2016Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
521832000
CY2016Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
31641000
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
85393000
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.00
CY2015Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18149000
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.99
CY2015Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6965000
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
590780000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
92702000
CY2015Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-288000
CY2015Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
143995000
CY2015Q4 us-gaap Interest Expense
InterestExpense
8493000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
150960000
CY2015Q4 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
741740000
CY2015Q4 us-gaap Investment Income Net
InvestmentIncomeNet
751000
CY2015Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
777000
CY2015Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51581000
CY2015Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93536000 shares
CY2015Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92790000 shares
CY2015Q4 us-gaap Profit Loss
ProfitLoss
92414000
CY2015Q4 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
461074000
CY2015Q4 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
26164000
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
97049000
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
CY2016Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25254000
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.84
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14780000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
687992000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
78079000
CY2016Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
127998000
CY2016Q4 us-gaap Interest Expense
InterestExpense
16356000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
142778000
CY2016Q4 us-gaap Health Care Organization Revenue
HealthCareOrganizationRevenue
830770000
CY2016Q4 us-gaap Investment Income Net
InvestmentIncomeNet
770000
CY2016Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
806000
CY2016Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49919000
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93347000 shares
CY2016Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92728000 shares
CY2016Q4 us-gaap Profit Loss
ProfitLoss
78079000
CY2016Q4 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
532952000
CY2016Q4 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
32737000

Files In Submission

Name View Source Status
0001193125-17-038250-index-headers.html Edgar Link pending
0001193125-17-038250-index.html Edgar Link pending
0001193125-17-038250.txt Edgar Link pending
0001193125-17-038250-xbrl.zip Edgar Link pending
d323709d10k.htm Edgar Link pending
d323709dex211.htm Edgar Link pending
d323709dex231.htm Edgar Link pending
d323709dex311.htm Edgar Link pending
d323709dex312.htm Edgar Link pending
d323709dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g323709g57x57.jpg Edgar Link pending
md-20161231.xml Edgar Link completed
md-20161231.xsd Edgar Link pending
md-20161231_cal.xml Edgar Link unprocessable
md-20161231_def.xml Edgar Link unprocessable
md-20161231_lab.xml Edgar Link unprocessable
md-20161231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending